1,2,3,4,6-penta-o-galloyl-beta-D-glucopyranoside inhibits proliferation of multiple myeloma cells accompanied with suppression of MYC expression

Duurenjargal Tseeleesuren, Rajni Kant, Chia Hung Yen, Hui Hua Hsiao, Yi Ming A. Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multiple myeloma (MM) still remains an incurable disease, therefore discovery of novel drugs boosts the therapeutics for MM. The natural compound 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranoside (PGG) has been shown to exhibit antitumor activities against various cancer cells. Here, we aim to evaluate antitumor effects of PGG on MM cell lines. PGG inhibited the growth of three different MM cell lines in a dose- and time-dependent manner. Cell cycle analysis revealed that PGG treatment caused cell cycle arrest in G1 phase. It also induced apoptosis which was indicated by significant increases of Annexin V positive cells, caspase 3/7 activity, and cleaved caspase 3 expression in PGG treated MM cell. Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death. We further demonstrated that PGG decreased MYC expression in protein and mRNA levels and reversed the mRNA expression of MYC target genes such as p21, p27, and cyclin D2. In addition, PGG also reduced protein expression of DEPTOR which is commonly overexpressed in MM. Unexpectedly, PGG antagonized the cytotoxic effect of bortezomib in the combination treatment. However, PGG treatment sensitized MM cells to another proteasome inhibitor MG132 induced cytotoxicity. Moreover, MYC inhibitor JQ1 enhanced the cytotoxic effect of bortezomib on MM cells. Our findings raised concerns about the combinatory use of bortezomib with particular types of chemicals. The evidence also provide useful insights into the combination of MYC and proteasome-inhibitors for MM therapy. Finally, PGG has a therapeutic potential for treatment of MM and further development is mandatory.

Original languageEnglish
Article number65
JournalFrontiers in Pharmacology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - Feb 2 2018
Externally publishedYes

Fingerprint

Rubiaceae
Multiple Myeloma
Proteasome Inhibitors
Caspase 3
Cyclin D2
Caspase 7
Cell Line
Messenger RNA
Annexin A5
G1 Phase
Drug Discovery
Cell Cycle Checkpoints
Cell Cycle
Proteins
Cell Death
Therapeutics

Keywords

  • Apoptosis
  • DEPTOR
  • G1 arrest
  • JQ1
  • Multiple myeloma
  • MYC
  • PGG
  • Proteasome-inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

1,2,3,4,6-penta-o-galloyl-beta-D-glucopyranoside inhibits proliferation of multiple myeloma cells accompanied with suppression of MYC expression. / Tseeleesuren, Duurenjargal; Kant, Rajni; Yen, Chia Hung; Hsiao, Hui Hua; Chen, Yi Ming A.

In: Frontiers in Pharmacology, Vol. 9, No. FEB, 65, 02.02.2018.

Research output: Contribution to journalArticle

@article{ecd90aa4981140c995754be99a2e0f00,
title = "1,2,3,4,6-penta-o-galloyl-beta-D-glucopyranoside inhibits proliferation of multiple myeloma cells accompanied with suppression of MYC expression",
abstract = "Multiple myeloma (MM) still remains an incurable disease, therefore discovery of novel drugs boosts the therapeutics for MM. The natural compound 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranoside (PGG) has been shown to exhibit antitumor activities against various cancer cells. Here, we aim to evaluate antitumor effects of PGG on MM cell lines. PGG inhibited the growth of three different MM cell lines in a dose- and time-dependent manner. Cell cycle analysis revealed that PGG treatment caused cell cycle arrest in G1 phase. It also induced apoptosis which was indicated by significant increases of Annexin V positive cells, caspase 3/7 activity, and cleaved caspase 3 expression in PGG treated MM cell. Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death. We further demonstrated that PGG decreased MYC expression in protein and mRNA levels and reversed the mRNA expression of MYC target genes such as p21, p27, and cyclin D2. In addition, PGG also reduced protein expression of DEPTOR which is commonly overexpressed in MM. Unexpectedly, PGG antagonized the cytotoxic effect of bortezomib in the combination treatment. However, PGG treatment sensitized MM cells to another proteasome inhibitor MG132 induced cytotoxicity. Moreover, MYC inhibitor JQ1 enhanced the cytotoxic effect of bortezomib on MM cells. Our findings raised concerns about the combinatory use of bortezomib with particular types of chemicals. The evidence also provide useful insights into the combination of MYC and proteasome-inhibitors for MM therapy. Finally, PGG has a therapeutic potential for treatment of MM and further development is mandatory.",
keywords = "Apoptosis, DEPTOR, G1 arrest, JQ1, Multiple myeloma, MYC, PGG, Proteasome-inhibitors",
author = "Duurenjargal Tseeleesuren and Rajni Kant and Yen, {Chia Hung} and Hsiao, {Hui Hua} and Chen, {Yi Ming A.}",
year = "2018",
month = "2",
day = "2",
doi = "10.3389/fphar.2018.00065",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - 1,2,3,4,6-penta-o-galloyl-beta-D-glucopyranoside inhibits proliferation of multiple myeloma cells accompanied with suppression of MYC expression

AU - Tseeleesuren, Duurenjargal

AU - Kant, Rajni

AU - Yen, Chia Hung

AU - Hsiao, Hui Hua

AU - Chen, Yi Ming A.

PY - 2018/2/2

Y1 - 2018/2/2

N2 - Multiple myeloma (MM) still remains an incurable disease, therefore discovery of novel drugs boosts the therapeutics for MM. The natural compound 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranoside (PGG) has been shown to exhibit antitumor activities against various cancer cells. Here, we aim to evaluate antitumor effects of PGG on MM cell lines. PGG inhibited the growth of three different MM cell lines in a dose- and time-dependent manner. Cell cycle analysis revealed that PGG treatment caused cell cycle arrest in G1 phase. It also induced apoptosis which was indicated by significant increases of Annexin V positive cells, caspase 3/7 activity, and cleaved caspase 3 expression in PGG treated MM cell. Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death. We further demonstrated that PGG decreased MYC expression in protein and mRNA levels and reversed the mRNA expression of MYC target genes such as p21, p27, and cyclin D2. In addition, PGG also reduced protein expression of DEPTOR which is commonly overexpressed in MM. Unexpectedly, PGG antagonized the cytotoxic effect of bortezomib in the combination treatment. However, PGG treatment sensitized MM cells to another proteasome inhibitor MG132 induced cytotoxicity. Moreover, MYC inhibitor JQ1 enhanced the cytotoxic effect of bortezomib on MM cells. Our findings raised concerns about the combinatory use of bortezomib with particular types of chemicals. The evidence also provide useful insights into the combination of MYC and proteasome-inhibitors for MM therapy. Finally, PGG has a therapeutic potential for treatment of MM and further development is mandatory.

AB - Multiple myeloma (MM) still remains an incurable disease, therefore discovery of novel drugs boosts the therapeutics for MM. The natural compound 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranoside (PGG) has been shown to exhibit antitumor activities against various cancer cells. Here, we aim to evaluate antitumor effects of PGG on MM cell lines. PGG inhibited the growth of three different MM cell lines in a dose- and time-dependent manner. Cell cycle analysis revealed that PGG treatment caused cell cycle arrest in G1 phase. It also induced apoptosis which was indicated by significant increases of Annexin V positive cells, caspase 3/7 activity, and cleaved caspase 3 expression in PGG treated MM cell. Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death. We further demonstrated that PGG decreased MYC expression in protein and mRNA levels and reversed the mRNA expression of MYC target genes such as p21, p27, and cyclin D2. In addition, PGG also reduced protein expression of DEPTOR which is commonly overexpressed in MM. Unexpectedly, PGG antagonized the cytotoxic effect of bortezomib in the combination treatment. However, PGG treatment sensitized MM cells to another proteasome inhibitor MG132 induced cytotoxicity. Moreover, MYC inhibitor JQ1 enhanced the cytotoxic effect of bortezomib on MM cells. Our findings raised concerns about the combinatory use of bortezomib with particular types of chemicals. The evidence also provide useful insights into the combination of MYC and proteasome-inhibitors for MM therapy. Finally, PGG has a therapeutic potential for treatment of MM and further development is mandatory.

KW - Apoptosis

KW - DEPTOR

KW - G1 arrest

KW - JQ1

KW - Multiple myeloma

KW - MYC

KW - PGG

KW - Proteasome-inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85041858938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041858938&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00065

DO - 10.3389/fphar.2018.00065

M3 - Article

AN - SCOPUS:85041858938

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - FEB

M1 - 65

ER -